Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.
LMVOS is a prospective, real-world registry lasting for 22 years. A total of 8000 patients with large- or medium-vessel occlusion will be enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute ischemic stroke with large- or medium-vessel occlusion | Acute ischemic stroke patients with large- or medium-vessel occlusion including all treatments. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Visit at D90 | Other | Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access. |
|
| Measure | Description | Time Frame |
|---|---|---|
| modified Rankin Scale (mRS) score | Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90±7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Excellent functional outcome | Proportion of subjects with mRS 0-1 at 90±7 days. | 90±7 days |
| Good functional outcome | Proportion of subjects with mRS 0-2 at 90±7 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of clinically significant intracranial hemorrhage | Incidence of sICH (Heidelberg criteria) measured at 36 hours | 36 hours |
| Incidence of any intracranial hemorrhage | Incidence of any intracranial hemorrhage (Heidelberg criteria) measured at 36 hours |
Inclusion Criteria:
The clinical diagnosis is acute ischemic stroke with large- or medium- vessel occlusion (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).
Informed consent from the patient or surrogate.
Exclusion Criteria:
No additional exclusion criteria.
Not provided
Not provided
Not provided
Not provided
Patients with acute ischemic stroke due to large- or medium-vessel occlusion will be enrolled and no additional exclusion criteria are set.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhengzhou Yuan, MD | Contact | +868303165661 | coneuro@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Zhengzhou Yuan, MD | Department of Neurology, Affiliated Hospital of Southwest Medical University, LuZhou, China. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Affiliated Hospital of Southwest Medical University | Recruiting | Luzhou | 646000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and Thrombosis.
| 90±7 days |
| mRS 0-3 | Proportion of subjects with mRS 0-3 at 90±7 days. | 90±7 days |
| Change of National Institutes of Health Stroke Scale (NIHSS) | Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 24 hours. | 24 hours |
| Change of National Institutes of Health Stroke Scale (NIHSS) | Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 7 days. | 7 days |
| Symptom-to-thrombolysis time (STT) | Time from onset of symptoms to thrombolytic therapy. | 24 hours |
| Door-to-Needle Time | Time from the arrival of stroke patient in emergency to initiation of thrombolysis therapy. | 24 hours |
| Door-to-Puncture Time (DPT) | ime from the arrival of stroke patient in emergency to groin puncture. | 24 hours |
| Onset-to-recanalization time | Time from symptom onset to the beginning of recanalization (recanalization defined as expanded TICI scale≥2b). | 24 hours |
| Door-to-Recanalization Time (DRT) | Time from the arrival of stroke patient in emergency to the beginning of recanalization (recanalization defined as expanded TICI scale≥2b). | 24 hours |
| Puncture-to-recanalization time | Time from groin puncture to recanalization (recanalization defined as expanded TICI scale≥2b). | 24 hours |
| 36 hours |
| All-cause mortality | All-cause mortality at 90±7 days | 90±7 days |
| Complications related to intravenous thrombolysis | Complications related to intravenous thrombolysis during hospitalization | up to 7 days |
| Complications related to endovascular treatment | Complications related to intravenous thrombolysis during hospitalization | up to 7 days |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |